Fractionated proton stereotactic radiotherapy (PSRT) is used to treat both adult and pediatric patients with a variety of diagnoses. A multi-disciplinary approach may involve combining PSRT with surgery, chemotherapy as well as conventional x-ray therapy. The need for combined-modality treatments depends on the specific disease being treated as well as patient’s medical history. Pediatric and adult patients benefit from proton stereotactic radiotherapy by sparing normal tissue, which would otherwise be compromised using conventional x-ray therapy alone.

Proton PSRT

This figure shows a patient lying on the robotic bed in one of the two gantry treatment rooms. The gantries are used to treat lesions throughout the body.

In pediatric patients, PSRT is used to treat tumors such as:

  • Astrocytoma
  • Craniopharyngioma
  • Ependymoma
  • Ewing sarcoma
  • Rhabdomyosarcoma
  • Tumors of the central nervous system (CNS) such as Medulloblastoma
  • Tumors of the eye such as Retinoblastoma

Special care is provided for young children, as they often require administration of general anesthesia for each PSRT treatment session. Board certified anesthesiologists provide this service as a regular part of the pediatric care. Pediatric nurses help the transition for parents and child in the induction and recovery process.

 PSRT Patient         PSRT Patient & Mom
Two-year-old patient, Mary Conroy and her mom Mari-Beth with pediatric nurse Rachel Bolton. Pediatric nurses provide extensive care during the induction and recovery process.

Mary and mom say hello to colorful monkeys as they enter the treatment room. The treatment delivery team includes an anesthesiologist who monitors vital signs during sedation and radiation therapists who align the patient and deliver the radiation. 


In adult patients, PSRT is used to treat:

  • Base of skull tumors such as Chordoma and Chondrosarcoma
  • Bone and soft tissue sarcomas including sacral, spinal and paraspinal sarcomas
  • Nasopharyngeal and Paranasal Sinus Carcinoma
  • Prostate Adenocarcinoma



Back to Top